FDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life* for People Living with Chronic Pain
- Proclaim ™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years* (Source: Abbott.com)
Source: Abbott.com - September 26, 2019 Category: Pharmaceuticals Source Type: news
U.S. FDA Clears Abbott's High Sensitivity Troponin-I Blood Test That Aids Doctors in Diagnosing Heart Attacks Faster and More Accurately
Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women (Source: Abbott.com)
Source: Abbott.com - September 25, 2019 Category: Pharmaceuticals Source Type: news
Abbott Hosts Conference Call for Third-Quarter Earnings
(Source: Abbott.com)
Source: Abbott.com - September 18, 2019 Category: Pharmaceuticals Source Type: news
Abbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children
- World's smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects (Source: Abbott.com)
Source: Abbott.com - September 17, 2019 Category: Pharmaceuticals Source Type: news
Abbott Named the Industry Leader in Sustainability for the Seventh Consecutive Year on the Dow Jones Sustainability Index (DJSI)
- Abbott achieves top scores across all three key areas of economic, social and environmental performance, earns more than double the average score in Health Care Equipment& Supplies industry sector (Source: Abbott.com)
Source: Abbott.com - September 16, 2019 Category: Pharmaceuticals Source Type: news
